BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 17605793)

  • 1. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.
    Bi LL; Pan G; Atkinson TP; Zheng L; Dale JK; Makris C; Reddy V; McDonald JM; Siegel RM; Puck JM; Lenardo MJ; Straus SE
    BMC Med Genet; 2007 Jul; 8():41. PubMed ID: 17605793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.
    Del-Rey M; Ruiz-Contreras J; Bosque A; Calleja S; Gomez-Rial J; Roldan E; Morales P; Serrano A; Anel A; Paz-Artal E; Allende LM
    Blood; 2006 Aug; 108(4):1306-12. PubMed ID: 16627752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
    Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
    Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
    Fisher GH; Rosenberg FJ; Straus SE; Dale JK; Middleton LA; Lin AY; Strober W; Lenardo MJ; Puck JM
    Cell; 1995 Jun; 81(6):935-46. PubMed ID: 7540117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
    Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
    Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
    Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome.
    Fleisher TA; Straus SE; Bleesing JJ
    Curr Allergy Asthma Rep; 2001 Nov; 1(6):534-40. PubMed ID: 11895618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
    Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
    Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation.
    Del-Rey MJ; Manzanares J; Bosque A; Aguiló JI; Gómez-Rial J; Roldan E; Serrano A; Anel A; Paz-Artal E; Allende LM
    Immunobiology; 2007; 212(2):73-83. PubMed ID: 17336828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
    Nagata S
    J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis.
    Fleisher TA
    Immunol Res; 2008; 40(1):87-92. PubMed ID: 18193364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome.
    Nabhani S; Hönscheid A; Oommen PT; Fleckenstein B; Schaper J; Kuhlen M; Laws HJ; Borkhardt A; Fischer U
    Clin Immunol; 2014 Dec; 155(2):231-7. PubMed ID: 25451160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune lymphoproliferative syndrome with somatic Fas mutations.
    Holzelova E; Vonarbourg C; Stolzenberg MC; Arkwright PD; Selz F; Prieur AM; Blanche S; Bartunkova J; Vilmer E; Fischer A; Le Deist F; Rieux-Laucat F
    N Engl J Med; 2004 Sep; 351(14):1409-18. PubMed ID: 15459302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.
    Infante AJ; Britton HA; DeNapoli T; Middelton LA; Lenardo MJ; Jackson CE; Wang J; Fleisher T; Straus SE; Puck JM
    J Pediatr; 1998 Nov; 133(5):629-33. PubMed ID: 9821419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
    Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
    Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Puck JM; Sneller MC
    Semin Immunol; 1997 Feb; 9(1):77-84. PubMed ID: 9106310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
    Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
    J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).
    Vacek MM; Schäffer AA; Davis J; Fischer RE; Dale JK; Adams S; Straus SE; Puck JM
    Clin Immunol; 2006 Jan; 118(1):59-65. PubMed ID: 16257267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II.
    Wang J; Zheng L; Lobito A; Chan FK; Dale J; Sneller M; Yao X; Puck JM; Straus SE; Lenardo MJ
    Cell; 1999 Jul; 98(1):47-58. PubMed ID: 10412980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in FAS and CASP8 genes may contribute to the development of ALPS phenotype: a study in 25 patients with probable ALPS.
    Tan Ç; Özgül RK; Çağdaş Ayvaz D; Tezcan İ; Sanal Ö
    Turk J Pediatr; 2015; 57(2):141-5. PubMed ID: 26690594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.